We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Biodel Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject™ and Plans Manufacturing Facility for VIAject™

News   Jan 08, 2008

 
Biodel Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject™ and Plans Manufacturing Facility for VIAject™
 
 
Advertisement
 

RELATED ARTICLES

Novel Strategy Generates Useful Compounds for Drug Synthesis

News

A team of scientists has designed a novel catalytic method that can generate useful chiral compounds. This new strategy could provide an effective synthetic way to design pharmaceutical products.

READ MORE

Existing Drugs Could Stop SARS-CoV-2 From Hijacking Cells

News

A team has analyzed how SARS-CoV-2, the virus that causes COVID-19, hijacks the proteins in its target cells. The scientists have also identified seven existing drugs that could disrupt these mechanisms.

READ MORE

Combination Therapy Improves Survival Rates for Women With Aggressive Endometrial Cancer in Phase 2 Trial

News

Yale Cancer Center scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE